Gliclazide Has Lowest Risk of Hypoglycemia of Newer SUs

This article originally appeared here.
Share this content:
Gliclazide Has Lowest Risk of Hypoglycemia of Newer SUs
Gliclazide Has Lowest Risk of Hypoglycemia of Newer SUs

FRIDAY, Aug. 26, 2016 (HealthDay News) -- Of the newer generation sulfonylureas (SUs), gliclazide is associated with the lowest risk of hypoglycemia when added to metformin, according to a systematic review and meta-analysis published online Aug. 3 in the British Journal of Clinical Pharmacology.

Stig Ejdrup Andersen, M.D., Ph.D., from Zealand University Hospital, and Mikkel Christensen, M.D., Ph.D., from Bispebjerg University Hospital, both in Denmark, conducted a systematic literature review to compare the relative risk of hypoglycemia with newer generation SUs added to metformin. Data were included for 13 trials of SUs and 14 of oral non-SU antihyperglycemic agents (16,260 patients).

The researchers found that hypoglycemia was the only adverse event reported. The risk of hypoglycemia was lowest with gliclazide versus glipizide (odds ratio [OR], 0.22; 95 percent credibility interval [CrI], 0.05 to 0.96), glimepiride (OR, 0.40; 95 percent CrI, 0.13 to 1.27), and glibenclamide (OR, 0.21; 95 percent CrI, 0.03 to 1.48), with comparable reductions in glycated hemoglobin of −0.66 to −0.84 percent. The definition of hypoglycemia varied across studies.

"When added to metformin, gliclazide was associated with the lowest risk of hypoglycemia between the newer generation SUs," the authors write. "Clinicians should consider the risk of hypoglycemia agent-specific when selecting an SU agent."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Low-Dose Hyaluronidase Can Remove Hyaluronic Acid Fillers

Low-Dose Hyaluronidase Can Remove Hyaluronic Acid Fillers

Greater resolution of nodules with hyaluronidase versus saline; more rapid resolution with higher doses

Improvement in Race-Based Disparities in Years of Life Lost

Improvement in Race-Based Disparities in Years of Life ...

Decline in race-based disparities in years of life lost seen in the United States from 1990 to 2014

Drug-Related Endocarditis Cases Up From 2007 to 2015

Drug-Related Endocarditis Cases Up From 2007 to 2015

Increase in endocarditis over nine-year study period mirrored increase in concomitant mixed drug use

is free, fast, and customized just for you!

Already a member?

Sign In Now »